Genmab A-S News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.01.24	Cracking The Code: Understanding Analyst Reviews For Genmab (Benzinga)
25.01.24	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
23.01.24	Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023 (GlobeNewswire)
23.01.24	Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen (GlobeNewswire)
09.01.24	TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer (GlobeNewswire)
03.01.24	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
02.01.24	Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
12.12.23	Genmab to Hold 2023 R&D Update and ASH Data Review Meeting (GlobeNewswire)
09.12.23	New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL) (GlobeNewswire)
05.12.23	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
28.11.23	9 Analysts Have This to Say About Genmab (Benzinga)
27.11.23	Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma (GlobeNewswire)
21.11.23	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
21.11.23	Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
09.11.23	Major Shareholder Announcement (GlobeNewswire)
09.11.23	Genmab to Present at Jefferies London Healthcare Conference (GlobeNewswire)
08.11.23	Major Shareholder Announcement (GlobeNewswire)
07.11.23	Genmab Announces Financial Results for the First Nine Months of 2023 (GlobeNewswire)
06.11.23	Ausblick: Genmab A-S legt Zahlen zum jüngsten Quartal vor (finanzen.net)
02.11.23	Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) (GlobeNewswire)
23.10.23	Erste Schätzungen: Genmab A-S gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
22.10.23	TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial (GlobeNewswire)
17.10.23	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023 (GlobeNewswire)
28.09.23	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
25.09.23	Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) (GlobeNewswire)
25.09.23	EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Ce (GlobeNewswire)
12.09.23	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
04.09.23	Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy (GlobeNewswire)
28.08.23	Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
15.08.23	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
03.08.23	Genmab Announces Financial Results for the First Half of 2023 (GlobeNewswire)
02.08.23	Ausblick: Genmab A-S legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
28.07.23	Genmab Updates 2023 Financial Guidance (GlobeNewswire)
21.07.23	Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) (GlobeNewswire)
20.07.23	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023 (GlobeNewswire)
19.07.23	Erste Schätzungen: Genmab A-S stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
28.06.23	Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (GlobeNewswire)
22.06.23	Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’ (GlobeNewswire)
20.06.23	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
09.06.23	Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 (GlobeNewswire)
08.06.23	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
06.06.23	Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
01.06.23	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
31.05.23	Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
25.05.23	Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress (GlobeNewswire)
23.05.23	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
19.05.23	EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLB (GlobeNewswire)
10.05.23	Genmab Announces Financial Results for the First Quarter of 2023 (GlobeNewswire)
09.05.23	Ausblick: Genmab A-S stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Genmab A-S

Aktien Top/Flop

Genmab A-S Peer Group Nachrichten

Meistgelesene Nachrichten